肝细胞癌癌组织Hic-5和COL1A1表达及其对术后生存的预测价值*

doi:10.3969/j.issn.1672-5069.2020.04.031

摘要/Abstract

摘要： 目的探讨肝细胞癌(HCC)组织氧化氢诱导的克隆基因-5(Hic-5)和I型胶原α1链(COL1A1)表达及其对HCC患者术后生存时间的预测价值。方法 2013年9月～2016年7月我院行肝癌切除术的HCC患者97例,术后取癌组织和癌旁肝组织。采用RT-PCR法和免疫组化法分别检测组织Hic-5和COL1A1 mRNA和蛋白表达。随访3年。结果 HCC患者癌组织Hic-5蛋白表达阳性率为53.6%,显著高于癌旁组织(16.5%,P＜0.05),其mRNA阳性率为66.0%,也显著高于癌旁组织(25.8%,P＜0.05);HCC患者癌组织COL1A1蛋白表达阳性率为71.1%,显著高于癌旁组织(25.8%,P＜0.05),其mRNA阳性率为78.4%,也显著高于癌旁组织(30.9%,P＜0.05);TNM Ⅰ～Ⅱ期患者癌组织Hic-5 mRNA阳性率为56.4%,显著低于Ⅲ～Ⅳ期者(78.6%,P＜0.05),COL1A1 mRNA阳性率为70.9%,也显著低于Ⅲ～Ⅳ期者(88.1%,P＜0.05),存在门静脉癌栓患者癌组织Hic-5 mRNA阳性率为82.5%,显著高于无门静脉癌栓者(54.4%,P＜0.05),COL1A1 mRNA阳性率为90.0%,显著高于无门静脉癌栓者(70.2%,P＜0.05);随访的87例患者生存时间为8.2~36.0个月,中位生存时间为36.0(14.6,36.0)个月;癌组织Hic-5阳性表达患者3 a生存时间为26.3(16.1,36.0)月,显著短于Hic-5阴性者【36.0(30.6,36.0),P＜0.05】,3 a无事件生存时间为21.4(11.7,36.0)月,也显著短于Hic-5阴性者【36.0(24.2,36.0),P＜0.05】。结论 HCC患者癌组织Hic-5阳性表达预示术后生存时间缩短,其原因可能与肿瘤分期差或门静脉存在癌栓有关。

关键词: 肝细胞癌, 肝癌切除术, 氧化氢诱导的克隆基因-5, I型胶原α1链, 生存

Abstract: Objective The aim of this study was to analyze the expression of hydrogen peroxide inducible clone-5 (Hic-5) and collagen type I alpha gene (COL1A1) in cancerous tissues and their predictive value for postoperative survival time of patients with hepatocellular carcinoma (HCC). Methods 97 patients with HCC underwent hepatectomy in our hospital during the period between September 2013 and July 2016, and all patients were followed-up for 36 months. The RT-PCR and immunohistochemistry were performed to detect Hic-5 and COL1A1 mRNA and their proteins in cancerous and non-cancerous tissues. Results The positive rate of Hic-5 protein in cancerous tissues was significantly higher than that in adjacent liver tissues (53.6% vs. 16.5, P<0.05), and the positive rate of Hic-5 mRNA was significantly higher than that in adjacent tissues (66.0% vs. 25.8%, P<0.05); the positive rate of COL1A1 protein in cancerous tissues was significantly higher than that in adjacent tissues (71.1% vs. 25.8%, P<0.05), and the positive rate of COL1A1 mRNA was significantly higher than that in adjacent tissues (78.4% vs. 30.9%, P<0.05); the positive rate of Hic-5 mRNA in patients with TNM stage I/II was significantly lower than that in with stage III/IV (56.4% vs. 78.6%, P<0.05), and the positive rate of COL1A1 mRNA was significantly lower than that in with stage III/IV (70.9% vs. 88.1%, P<0.05); the positive rate of Hic-5 in patients with portal vein thrombosis was significantly higher than that in without (82.5% vs. 54.4%, P<0.05), and the positive rate of COL1A1 mRNA was significantly higher than that in without (90.9% vs. 70.2%, P<0.05); the medium survival in 87 followed-up patients was 8.2 to 36.0 months[36.0(14.6,36.0) m; the 3-year cumulative survival in patients with positive Hic-5 expression was significantly shorter than that in with negative [26.3(16.1,36.0) m vs. 36.0(30.6,36.0) m, P<0.05], and the 3-year cumulative event-free survival was also significantly shorter than that in with negative [21.4(11.7,36.0) m vs. 36.0(24.2,36.0]m, P<0.05). Conclusion The positive Hic-5 expression in cancerous tissues in patients with HCC hint poor prognosis, which might be related to the advanced tumor stage and portal vein thrombosis.

Key words: Hepatoma, Hepatectomy, Hydrogen peroxide inducible clone-5, Collagen type I alpha gene, Survival

顾世玉, 秦文举, 高建芝, 薛明辉. 肝细胞癌癌组织Hic-5和COL1A1表达及其对术后生存的预测价值^*[J]. 实用肝脏病杂志, 2020, 23(4): 576-580.

Gu Shiyu, Qin Wenju, Gao Jianzhi, et al. Poor prognosis of patients withhepatocellular carcinoma after hepatectomy with high cancerous tissue Hic-5 and COL1A1 expression[J]. Journal of Practical Hepatology, 2020, 23(4): 576-580.

参考文献

[1]Macaron C, Hanouneh I A, Zein N N. Incidence and risk factors of hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology, 2015, 52(6):2240-2240.
[2]Yoon Y I, Kim K H, Kang S H, et al. Purelaparoscopic versus open right hepatectomy for hepatocellular carcinoma in patients with cirrhosis: A propensity score matched analysis. Ann Surg, 2017, 265(5):856-863.
[3]Ally A, Balasundaram M, Carlsen R, et al. Comprehensive andintegrative genomic characterization of hepatocellular carcinoma. Cell, 2017, 169(7):1327-1341.
[4]Gulvady A C, Dubois F, Deakin N O, et al. Hic-5expression is a major indicator of cancer cell morphology, migration and plasticity in three-dimensional matrices. Mol Bio Cell, 2018, 29(13):1704-1717.
[5]Li J, Ding Y, Li A. Identification of COL1A1 and COL1A2 as candidate prognostic factors in gastric cancer. World J Surg Oncol, 2016, 14(1):297-301.
[6]罗程, 陈琪, 方程, 等. Hic-5基因在胆管纤维化中的表达. 实用医学杂志, 2018, 34(20):51-55.
[7]Tao R, Fan X, Yu H, et al. MicroRNA-29b-3p prevents Schistosoma Japonicum‐induced liver fibrosis by targeting COL1A1 and COL3A1. J Cell Biochem, 2018, 8(1):102-110.
[8]Pirisi M, Leutner M, Pinato D J, et al. Reliability and reproducibility of the edmondson grading of hepatocellular carcinoma using paired core biopsy and surgical resection specimens. Arch Pathol Lab Med, 2010, 134(12):1818-1822.
[9]张杰, 段伯焕, 朱功兵. 肝细胞癌患者外科手术根治术后生存分析. 实用肝脏病杂志, 2017, 20(1):93-96.
[10]Sheta R, Wang Z Q, Bachvarova M, et al. Hic-5 regulates epithelial to mesenchymal transition in ovarian cancer cells in a TGFβ1-independent manner. Oncotarget, 2017, 8(47):82506-82530.
[11]Lei X F, Fu W, Kim-Kaneyama J R, et al. Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice. J Hepatol, 2016, 64(1):110-117.
[12]张金莲, 蔡兆根, 吴琼, 等. 肝细胞癌患者血清和肝组织microRNAlet-7水平及其与临床预后的关系. 实用肝脏病杂志, 2018, 21(3):119-122.
[13]Schleit J, Bailey S S, Tran T, et al. Molecularoutcome, prediction, and clinical consequences of splice variants in COL1A1, which encodes the proα1(I) chains of type I procollagen. Hum Mutat, 2015, 36(7):728-739.
[14]Zhang Z, Wang Y, Zhang J, et al. COL1A1 promotes metastasis in colorectal cancer by regulating the WNT/PCP pathway. Mol Med Rep, 2018, 17(4):1-6.
[15]Jolly L A, Novitskiy S V, Owens P, et al. Fibroblast-mediated collagen remodeling within the tumor microenvironment facilitates progression of thyroid cancers driven by BrafV600E and Pten loss. Cancer Res, 2016, 76(7):1804-1813.
[16]Nick H, Andrew M. Extracellular matrix-induced Hic-5 expression in glomerular mesangial cells leads to a prosclerotic phenotype independent of TGF-β. Faseb J, 2015, 29(12):4956-4967.
[17]Zhang S, Gong Y, Xiao J, et al. A COL1A1promoter-controlled expression of TGF-β soluble receptor inhibits hepatic fibrosis without triggering autoimmune responses. Dig Dis Sci, 2018, 63(10):2662-2672.
[18]Goreczny G J, Forsythe I J, Turner C E. Hic-5regulates fibrillar adhesion formation to control tumor extracellular matrix remodeling through interaction with tensinl. Oncogene, 2018, 37(13):1699-1713.
[19]Shen L, Yang M, Lin Q, et al. COL11A1 is overexpressed in recurrent non-small cell lung cancer and promotes cell proliferation, migration, invasion and drug resistance. Oncol Rep, 2016, 36(2):877-885.
[20]Omata M, Cheng AL, Kokudo N, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int, 2017, 11(4): 317–370.

肝细胞癌癌组织Hic-5和COL1A1表达及其对术后生存的预测价值^*

Poor prognosis of patients withhepatocellular carcinoma after hepatectomy with high cancerous tissue Hic-5 and COL1A1 expression

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张静, 周新民. 应用重组人血小板生成素减少肝硬化患者术前血小板输注疗效初步研究^*[J]. 实用肝脏病杂志, 2020, 23(4): 552-555.
[2]	冯涛, 胡伟, 滕步伟, 李伟. ALBI联合剩余肝体积对HBV相关原发性肝癌患者肝切除术后肝衰竭发生的预测价值^*[J]. 实用肝脏病杂志, 2020, 23(4): 585-588.
[3]	崔喆,徐兰. 基于多数据库分析肝细胞癌组织FAM49B基因水平及其临床意义[J]. 实用肝脏病杂志, 2020, 23(3): 413-418.
[4]	徐学清,李炳超,冯铠莉. CT增强纹理技术对TACE治疗的原发性肝癌患者术后肿瘤短期进展的预测价值[J]. 实用肝脏病杂志, 2020, 23(3): 423-426.
[5]	王亮亮,杨波,张卫国. 荧光腹腔镜肝切除术与常规腹腔镜肝切除术治疗HCC患者效果比较[J]. 实用肝脏病杂志, 2020, 23(3): 427-430.
[6]	王玮, 杜晓菲, 路运健. 术前NLR水平对TACE联合MWA治疗的巨块型原发性肝癌患者生存时间的影响^*[J]. 实用肝脏病杂志, 2020, 23(2): 260-263.
[7]	李天纵, 周松, 周石. 肝细胞癌患者TACE治疗前后血清miR-145水平变化及其临床意义[J]. 实用肝脏病杂志, 2020, 23(2): 264-267.
[8]	胡鸿, 廖运国, 魏欣, 唐梓瑜, 邓丹, 蒲嘉骐, 钟立明. ¹²⁵I粒子植入或3DCRT联合TACE治疗晚期原发性肝癌患者临床疗效对比研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 268-271.
[9]	唐浩, 宋文渊, 曾凯. 两种手术方法对严重外伤性肝破裂患者生存率的影响^*[J]. 实用肝脏病杂志, 2020, 23(2): 280-283.
[10]	刘潇, 何年安, 叶显俊, 刘力, 付文学, 陈姣姣. 超声造影对肝细胞癌与肝转移癌的鉴别诊断价值分析[J]. 实用肝脏病杂志, 2020, 23(1): 94-97.
[11]	石莹莹, 王元喜. 应用肝脏影像报告与数据管理系统诊断肝细胞癌的价值研究^*[J]. 实用肝脏病杂志, 2020, 23(1): 98-101.
[12]	马宁, 戴晓雯, 吴建江. 肝部分切除术患者目标导向性液体治疗疗效及安全性研究^*[J]. 实用肝脏病杂志, 2020, 23(1): 102-105.
[13]	高莉, 高屹, 尹秋萍. CT灌注成像联合彩色多普勒超声造影辨别肝脏结节性病变性质临床价值探讨^*[J]. 实用肝脏病杂志, 2020, 23(1): 106-109.
[14]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[15]	朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723.